MC DX4
Alternative Names: MC-DX4Latest Information Update: 28 Jun 2025
At a glance
- Originator miRecule
- Class Antibodies; Antisense oligonucleotides; Drug conjugates; Immunoconjugates
- Mechanism of Action DUX4L1 protein expression inhibitors; Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Facioscapulohumeral muscular dystrophy
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for research development in Facioscapulohumeral-muscular-dystrophy in USA (Parenteral)
- 04 Oct 2022 miRecule and Sanofi agree to co-promote and co-develop MC DX4 for Facioscapulohumeral muscular dystrophy
- 07 Jun 2021 Pharmacodynamics data from early research in Facioscapulohumeral muscular dystrophy presented at the 27th Annual FSHD International Research Congress (IRC-2020)